
    
      The objective of this observational study is to collect effectiveness and safety data on the
      labelled use of buprenorphine transdermal patches (Transtec 35 μg/h and 52.5 μg/h) under
      regular and routine clinical conditions in Taiwan for cancer patients with moderate to severe
      cancer pain (NRS Score>=4) and strong opioids are needed for their pain treatment.
    
  